Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD
Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Apr 12, 2024
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new treatment called Anti-CD25 rhMAb for patients with a condition known as steroid-refractory chronic graft-versus-host disease (cGVHD) that affects the liver after receiving a stem cell transplant. In simple terms, cGVHD can happen when the new immune cells from the donor attack the recipient's body, leading to various complications. The study will compare the effects of this new treatment to traditional therapies to see which works better and is safer for patients.
To participate in this trial, patients need to be between the ages of 16 and 65, have had a stem cell transplant, and have experienced liver cGVHD that has not responded to standard steroid treatment. They should not have had more than four other treatments for this condition before joining the study. If eligible, participants will receive either the new treatment or standard care after giving their consent. It’s important to note that the trial is not yet recruiting participants, so there’s still time to learn more before deciding to take part.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 16 and 65 years
- • 2. Received allogeneic hematopoietic stem cell transplantation
- • 3. Developed chronic GVHD in the liver after transplantation
- • 4. Ineffective prednisone treatment prior to screening
- • 5. Received ≤4 lines of systemic therapy prior to screening
- • 6. After informed consent, the patient agreed to receive anti-CD25 rhMAb treatment
- Exclusion Criteria:
- • 1. Elevation of bilirubin, ALT, or alkaline phosphatase due to reasons other than chronic GVHD
- • 2. No prior treatment with prednisone
- • 3. Overlap syndrome
- • 4. Uncontrolled active infection
- • 5. Organ failure
- • 6. Early progression or recurrence of hematologic diseases
- • 7. Allergy to anti-CD25 rhMAb
- • 8. Received other interleukin-2 receptor monoclonal antibody treatment due to various reasons within one month after transplantation
- • 9. Participated in other clinical studies within one month
About Peking University People's Hospital
Peking University People's Hospital is a leading clinical research institution in China, renowned for its commitment to advancing medical knowledge and improving patient care through innovative clinical trials. Affiliated with Peking University, the hospital integrates cutting-edge research, comprehensive healthcare services, and a multidisciplinary team of experts to facilitate the development of new therapies and medical interventions. With a strong focus on patient safety and ethical standards, Peking University People's Hospital is dedicated to conducting rigorous clinical trials that contribute to the global medical community and enhance the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported